Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chimera Therapeutics
Carlton, Victoria, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Chimeric Therapeutics has initiated four Phase 1 clinical trials across three cell therapy assets targeting solid tumors and hematologic malignancies, with early dose escalation data expected in 2025. Lead program (CDH17 CAR T) is in Phase 1 for GI cancers, with a separate CLTX program for glioblastoma and an allogeneic NK cell platform in AML[2][5].
- Therapeutic areas
- HematologyOncology
- Modalities
- CAR-T cell therapyNK cell therapyCell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Chimera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chimera Therapeutics.